Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
Li
Lin Nan
LN
Dong
Peng Wen
PW
D000077384:Anastrozole; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D004164:Diphosphonates / Q000627:therapeutic use; D018572:Disease-Free Survival; D004359:Drug Therapy, Combination; D005260:Female; D017273:Goserelin / Q000627:therapeutic use*; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use; D009570:Nitriles / Q000627:therapeutic use; D017697:Premenopause; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D013629:Tamoxifen / Q000627:therapeutic use; D014230:Triazoles / Q000627:therapeutic use; D000077211:Zoledronic Acid
D000077384:Anastrozole; D018931:Antineoplastic Agents, Hormonal; D004164:Diphosphonates; D017273:Goserelin; D007093:Imidazoles; D009570:Nitriles; D018719:Erb-b2 Receptor Tyrosine Kinases; D013629:Tamoxifen; D014230:Triazoles; D000077211:Zoledronic Acid